SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

Ryjunea

LGND·Ligand Pharmaceuticals
BEARISH
Drug Impact Rating3/10
Trial phase
Approved (EU/UK/Japan); Filed/PDUFA review in US
Time to market
Already marketed in the EU (European Commission approval June 2025) and UK (MHRA approval) under Santen's commercial operations. Launched in Japan as RYJUSEA in April 2025. US approval timeline uncertain after the CRL and pending tomorrow's AdComm.
Why 3/10
Ryjunea is already approved and commercializing in the EU, UK, and Japan. The next catalyst is the FDA Advisory Committee meeting on October 30, 2026 for US approval, but Ligand holds only EMEA royalty rights (acquired for $23M) and Ryjunea is one of over 200 assets in Ligand's diversified royalty portfolio. With no hard binary catalyst that drives LGND's share price, impactScore is 3.
Actionable Insight BEARISH

The FDA Dermatologic and Ophthalmic Drugs Advisory Committee meets October 30, 2026 to review SYD-101/Ryjunea for US approval. FDA briefing documents released October 28 question the drug's efficacy at slowing myopia progression. An unfavorable AdComm vote would likely keep Ryjunea out of the US market indefinitely; a favorable vote would still face an FDA decision. For LGND this catalyst matters less than for Sydnexis since Ligand holds only EMEA royalty rights.

Price Chart

Loading chart...

Executive Summary

Ryjunea (atropine sulfate 0.01%) is a low-dose atropine eye drop approved in the EU, UK, and Japan to slow pediatric myopia progression. Ligand Pharmaceuticals (LGND) acquired EMEA royalty rights from developer Sydnexis for $23 million in September 2026, receiving a tiered low-double-digit to high-teens royalty on EMEA sales. The FDA previously issued a Complete Response Letter in October 2025, and the advisory committee meeting scheduled for October 30, 2026 just one day from now faces skeptical FDA briefing documents questioning efficacy. For LGND, this is a small, non-core royalty interest among more than 200 portfolio assets.

How It Works

A nightly low-dose atropine eye drop that relaxes the eye's focusing muscle, which helps slow the worsening of nearsightedness (myopia) in children. Atropine is a well-known anticholinergic drug; at this very low concentration (0.01%) it reduces progression of eyeball elongation without causing the severe side effects of higher doses.

Trial Status

The pivotal Phase 3 STAR trial (847 patients) met its primary endpoint (proportion with confirmed myopia progression of -0.75D) and key secondary endpoint (annual progression rate). Data were presented at AMCP Nexus 2025 and AAPOS 2026. Despite meeting endpoints, the FDA issued a Complete Response Letter in October 2025 stating the data did not sufficiently demonstrate effectiveness. The FDA has since scheduled an Advisory Committee meeting for October 30, 2026.

The Two-Sided Case

▲ Bull Case4
Ryjunea is the first and only approved pharmacologic treatment in the EU and UK for slowing pediatric myopia, addressing a large and growing global market (myopia projected to affect half the world by 2050).
The Phase 3 STAR trial met its primary efficacy endpoint, and subgroup analyses presented at AAPOS 2026 showed benefit particularly in fast progressors.
Ligand paid only $23M upfront for the EMEA royalty stream, a small outlay for potential decades of tiered low-double-digit to high-teens royalties with no further development cost.
No FDA-approved drug for pediatric myopia exists in the US, creating a large unmet-need commercial opportunity if SYD-101 ultimately clears the FDA.
▼ Bear Case5
FDA briefing documents released October 28, 2026 question whether SYD-101 is effective at slowing myopia, and the agency already issued a Complete Response Letter in October 2025 citing insufficient evidence of efficacy despite the STAR trial meeting its primary endpoint.
The FDA Advisory Committee vote tomorrow could be negative, effectively blocking US approval and limiting Ryjunea's commercial opportunity to the smaller EMEA market where Santen handles commercialization.
Competing low-dose atropine programs (Vyluma's NVK002) also received FDA CRLs, suggesting the agency has a high bar for atropine in myopia and may require additional large trials.
Ligand's interest is limited to EMEA sales royalties, a relatively small addressable market compared to the US. At $23M upfront, this is a minor position in Ligand's >200-asset portfolio and is unlikely to materially move LGND shares.
Insider selling at Ligand has been persistent (CLO Reardon sold shares in several tranches in Sept-Oct 2026 around $285-$307), and the weighted short volume ratio of ~68% suggests elevated bearish positioning.

Upcoming Catalysts

  • FDA Dermatologic and Ophthalmic Drugs Advisory Committee meeting for SYD-101/Ryjunea on October 30, 2026 (tomorrow)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Ligand Pharmaceuticals PRESS-RELEASE LGND ·Originating report

Sources · 10

Hover a chip for the title
1 investor.ligand.com2 bioworld.com3 ema.europa.eu4 santen.com5 sydnexis.com6 sydnexis.com7 fda.gov8 sec.gov9 ophthalmologytimes.com10 biospace.com